Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
October 26 2020 - 4:01PM
Business Wire
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced the closing of
its public offering of 16,100,000 shares of its common stock, which
included the exercise in full of the underwriters’ option to
purchase additional shares, at a public offering price of $3.00 per
share. All of the shares sold in the offering were sold by Aptinyx.
The gross proceeds from the offering, before deducting underwriting
discounts and commissions and offering expenses payable by Aptinyx,
were $48.3 million.
SVB Leerink, Piper Sandler and Cantor are acting as joint
bookrunning managers for the offering. Wedbush PacGrow is acting as
passive bookrunning manager and H.C. Wainwright & Co. is acting
as lead manager for the offering.
Aptinyx intends to use the net proceeds received from the
offering to advance the development of its novel NMDA receptor
modulators, including NYX-2925, NYX-783, and NYX-458, in
development for chronic pain, PTSD, and cognitive impairment,
respectively, and for working capital and other general corporate
purposes.
The shares of common stock in the public offering were issued by
Aptinyx pursuant to a shelf registration statement that was
previously filed with, and declared effective by, the Securities
and Exchange Commission (the “SEC”). The offering was made only by
means of the written prospectus and prospectus supplement that form
a part of the registration statement. A final prospectus supplement
and the accompanying prospectus relating to the public offering
were filed by the Company with the SEC. Copies of the final
prospectus supplement and the accompanying prospectus may be
obtained, when available, on the SEC's website at
http://www.sec.gov or by contacting SVB Leerink LLC, Attention:
Syndicate Department, One Federal St., 37th Floor, Boston, MA,
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com; or Piper Sandler & Co., Attn:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN,
55402, by telephone at (800) 747-3924, or by email at
prospectus@psc.com; or Cantor Fitzgerald & Co., Attention:
Capital Markets, 499 Park Ave., 6th Floor, New York, NY, 10022, or
by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the expected use of proceeds of the offering. Risks that contribute
to the uncertain nature of the forward-looking statements include:
the success, cost, and timing of the company’s product candidate
development activities and planned clinical studies; the company’s
ability to execute on its strategy; positive results from a
clinical study may not necessarily be predictive of the results of
future or ongoing clinical studies; regulatory developments in the
United States and foreign countries; the company’s estimates
regarding expenses, future revenue, and capital requirements, and
other financial results; as well as those risks and uncertainties
set forth in the company’s most recent Annual Report on Form 10-K
and subsequent filings with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Aptinyx undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201026005816/en/
Investor Contact: Nick Smith Aptinyx Inc. ir@aptinyx.com
847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024